Last updated on April 2019

Study to Assess the Long-term Safety Tolerability Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Brief description of study

This is an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. Approximately 80 subjects (at least 60 subjects with moderate severity) will be enrolled. subjects will be stratified by weight. It is expected that subjects will be enrolled in about 40 centers worldwide.

Clinical Study Identifier: NCT03668613

Contact Investigators or Research Sites near you

Start Over

Novartis Investigative Site

Rzeszow, Poland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.